Hemodynamic Effects of the Combination of Carvedilol and Pimobendan in Dogs
ACVIM 2008
M. Uechi; N. Isayama; T. Mizuno; T. Ebisawa; S. Yamano; M. Mizuno; T. Mizukoshi
Nihon University
Kanagawa, Japan

The objective was to evaluate the influence on cardiac function of a combination of carvedilol, which is a β-blocker and pimobendan, which is a Ca sensitizer. Six beagle dogs (8.7-12.8 kg) were used. The dogs were divided into 4 groups that were placebo, the carvedilol group, pimobendan group, and the combination group. Placebo and carvedilol (1 mg/kg) and/or pimobendan (0.4 mg/kg) were orally administered. Heart rate, arterial blood pressure, left ventricular fractional shortening, and left ventricle internal diameter were measured before and after 3-hour administration. Heart rate was not different in placebo (94 ± 21 bpm), the carvedilol group (88 ± 11 bpm), the pimobendan group (99 ± 22 bpm), and the combination group (100 ± 19 bpm). The pimobendan group (59 ± 3%) and combination group (55 ± 3%) revealed significant elevation of fractional shortening compared with the control (41 ± 5%) and the carvedilol group (40 ± 11%). In the combination group (125 ± 15 mmHg), (P < 0.01) blood pressure fell significantly compared with the placebo (141 ± 14 mmHg), carvedilol group (131 ± 18 mmHg), and pimobendan group (139 ± 22 mmHg). It is suggested that pimobendan indicated a positive inotropic effect in the presence of carvedilol without affecting the heart rate, and the vasodilator action of both medicines was enhanced by the combination of carvedilol and pimobendan.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Masami Uechi

MAIN : SA Cardiology : Carvedilol & Pimobendan
Powered By VIN